Veeva Systems (NYSE:VEEV) Issues Q2 2026 Earnings Guidance

Veeva Systems (NYSE:VEEV - Get Free Report) updated its second quarter 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.890-1.900 for the period, compared to the consensus estimate of 1.880. The company issued revenue guidance of $766.0 million-$769.0 million, compared to the consensus revenue estimate of $765.3 million. Veeva Systems also updated its FY 2026 guidance to 7.630-7.630 EPS.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on VEEV shares. Morgan Stanley lifted their price objective on Veeva Systems from $201.00 to $210.00 and gave the stock an "underweight" rating in a research note on Thursday. Stifel Nicolaus lifted their price objective on Veeva Systems from $272.00 to $295.00 and gave the stock a "buy" rating in a research note on Thursday. Wells Fargo & Company lifted their price objective on Veeva Systems from $285.00 to $300.00 and gave the stock an "overweight" rating in a research note on Thursday. Needham & Company LLC lifted their price objective on Veeva Systems from $270.00 to $300.00 and gave the stock a "buy" rating in a research note on Thursday. Finally, Citigroup lifted their price objective on Veeva Systems from $265.00 to $329.00 and gave the stock a "buy" rating in a research note on Friday. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, Veeva Systems has a consensus rating of "Moderate Buy" and an average price target of $269.00.

Veeva Systems Stock Up 0.4%

VEEV traded up $0.99 during trading on Friday, hitting $280.03. The company's stock had a trading volume of 3,578,987 shares, compared to its average volume of 1,147,282. The firm has a market capitalization of $45.56 billion, a P/E ratio of 69.14, a PEG ratio of 1.89 and a beta of 0.96. Veeva Systems has a twelve month low of $170.25 and a twelve month high of $285.70. The stock's fifty day moving average price is $230.48 and its 200-day moving average price is $227.86.

Veeva Systems (NYSE:VEEV - Get Free Report) last issued its earnings results on Wednesday, May 28th. The technology company reported $1.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.74 by $0.23. Veeva Systems had a return on equity of 13.56% and a net margin of 25.07%. The company had revenue of $759.04 million for the quarter, compared to analysts' expectations of $728.38 million. During the same period last year, the business earned $1.50 EPS. Veeva Systems's quarterly revenue was up 16.7% compared to the same quarter last year. Equities research analysts expect that Veeva Systems will post 4.35 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Timothy S. Cabral sold 3,882 shares of the company's stock in a transaction on Friday, April 4th. The stock was sold at an average price of $216.83, for a total transaction of $841,734.06. Following the completion of the sale, the director now owns 5,500 shares in the company, valued at approximately $1,192,565. This represents a 41.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Thomas D. Schwenger sold 1,200 shares of the company's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $220.97, for a total value of $265,164.00. Following the sale, the insider now owns 25,889 shares of the company's stock, valued at $5,720,692.33. This trade represents a 4.43% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,869 shares of company stock worth $1,284,917 in the last ninety days. Corporate insiders own 10.30% of the company's stock.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.